STRATEGIC GROWTH OPPORTUNITIES IN CARDIOVASCULAR INTERVENTIONAL PRODUCT MARKETS, 2000-2010

200 Pages | 60 Exhibits | 2000 Analysis | Forecasts Through 2010 Product Family: Market Reports




OVERVIEW:
This report is a detailed market and technology assessment and forecast of the current and emerging products in interventional cardiology. The report addresses the current state of development of these technologies, including an assessment of the market size and competitor shares for companies with products on the market. The report assesses current status and outlook for development of the technologies, products and markets, providing a ten-year forecast of the evolution of the market describing the expected timeline and market impact of technologies coming to market. The analysis reveals windows of opportunity for current and hopeful market competitors.

TABLE OF CONTENTS:
EXECUTIVE SUMMARY

I.  Novel Coronary Revascularization Systems
	Ia.  Transmyocardial Revascularization
	Ib.  Photoangioplasty
	Ic.  Therapeutic Angiogenesis
II.  Emerging Stroke Prevention Systems
III.  AAA Stent Graft Systems
IV.  Vascular Puncture Closure Devices (VPCD)
 
Exhibit ES-1: Projected U.S. Epidemiology of Major Life-Threatening Cardiovascular Disorders, 2000-2005-2010
Exhibit ES-2: Projected Procedure Mix in Interventional Management of Major Cardiovascular Disorders, 2000-2010 (#000)
Exhibit ES-3:  U.S. PTCA vs. CABG, 1999-2010
Exhibit ES-4:  U.S. Primary TMR/PTMR vs. CABG, 1999-2010
Exhibit ES-5:  U.S. Carotid Endarterectomies vs. Carotid Stenting, 1999-2010
Exhibit ES-6:  U.S. AAA Repair, Surgery vs. Endograft, 1999-2010
Exhibit ES-7:  U.S. Vascular Puncture Closure, Compression vs. Device Closure, 1999-2010
Exhibit ES-8: U.S. Markets for Novel Cardiovascular Interventional Products, 1999-2010  ($mil)
Exhibit ES-9: U.S. Markets for Novel Coronary Revascularization Systems, 1999-2010 ($ mil)
Exhibit ES-10: U.S. Markets for Interventional Stroke Prevention Systems, 1999-2010
Exhibit ES-11: U.S. Markets for AAA Endovascular Repair Systems, 1999-2010
Exhibit ES-12: U.S. Markets for Vascular Puncture Closure Systems, 1999-2010

Section 1:  Cardiovascular Disorders - Clinical and Statistical Overview

1.1  Etiology of Cardiovascular Disease
1.2  Prevalent Cardiovascular Diseases Targeted by Novel Therapies
	1.2.1  Atherosclerosis
		1.2.1.1   Complications Associated with Atherosclerosis
		1.2.1.2  Causes and Mechanisms
	1.2.2  Ischemic Heart Disease
	1.2.3  Angina Pectoris
		1.2.3.1 Characterizing Angina
			1.2.3.1.1  Stable Angina
			1.2.3.1.2  Variant/Prinzmetal Angina
		1.2.3.2  Classifying Angina and Treatment Options
	1.2.4  Acute Myocardial Infarction
		1.2.4.1  Treatment for AMI
	1.2.5  Aortic Aneurysms
		1.2.5.1  AA Treatment
			1.2.5.1.1  Surgical Intervention
			1.2.5.1.2  Endovascular Approach
	1.2.6  Stroke
		1.2.6.1  Cerebral Thrombosis and Embolism
		1.2.6.2  Hemorrhagic Stroke
		1.2.6.3  Incidence and Treatment of Stroke
	1.2.7  Deep Venous Thrombosis and Pulmonary Embolism
		1.2.7.1  Thrombogenic Stimuli
		1.2.7.2  Pulmonary Embolism
	1.2.8  Congestive Heart Failure
		1.2.8.1  CHF Management

Exhibit 1-1: Estimated and Projected U.S. Epidemiology of Major Life-Threatening Cardiovascular Disorders, 2000-2005-2010

Section 2:  Established and Emerging Interventional Therapies for Major Life-Threatening Cardiovascular Disorders

2.1  Management of Advanced Coronary Artery Disease
	2.1.1  Coronary Artery Bypass Graft Surgery
		2.1.1.1  Less Invasive Techniques
			2.1.1.1.1  "Off-Pump"  CABG
			2.1.1.1.2  Minimally Invasive Direct CABG
			2.1.1.1.3  Port Access CABG
		2.1.1.2  Clinical Indications
			2.1.1.2.1  Complications and Outcome
			2.1.1.2.2  Associated Risk Factors
			2.1.1.2.3  CABG vs. PTCA
		2.1.1.3  End-User Trends and Procedure Volumes
			2.1.1.3.1  Penetration Forecast
	2.1.2  Percutaneous Transluminal Coronary Angioplasty/Stenting
		2.1.2.1  Advent of Stenting
		2.1.2.2  Clinical Indications and Outcomes
		2.1.2.3  End-Use Trends
			2.1.2.3.1 Procedural Volumes
			2.1.2.3.2 Emerging Therapies
	2.1.3  Transmyocardial Revascularization
		2.1.3.1  Procedural Details
		2.1.3.2  Percutaneous Transmyocardial Revascularization
		2.1.3.3  Clinical Indications
			2.1.3.3.1  Projected Patient Volume
		2.1.3.4  Outcomes
		2.1.3.5 Transmyocardial Revascularization Systems on the Market and Under Development
			2.1.3.5.1  Laser-Based TMR & PTMR Systems
				2.1.3.5.1.1  PLC Medical
				2.1.3.5.1.2  Eclipse Surgical Technologies
					2.1.3.5.1.2.1 PTMR Axcis System
			2.1.3.5.2  Biosense Webster
			2.1.3.5.3  Radiofrequency Ablation-Based PTMR Systems
				2.1.3.5.3.1  Boston Scientific
				2.1.3.5.3.2  Radius Medical
			2.1.3.5.4  Mechanical PTMR Technology
				2.1.3.5.4.1  Angiotrax
			2.1.3.5.5  Other Emerging Competitors
	2.1.4  Photoangioplasty
		2.1.4.1  Principles and Mechanisms of Photoangioplasty
			2.1.4.1.1 Acute Effects and Desired Characteristics
		2.1.4.2  Photoangioplasty Products Under Development and Trial Results
			2.1.4.2.1  Pharmacyclics
				2.1.4.2.1.1  Preclinical Antrin Studies
				2.1.4.2.1.2  Clinical Studies Using Antrin
					2.1.4.2.1.2.1  Peripheral Artery Disease
				2.1.4.2.1.3  Coronary Artery Disease
			2.1.4.2.2  Miravant Medical Technologies
			2.1.4.2.3  QLT Photo Therapeutics Inc.
			2.1.4.2.4  Other Emerging Companies
			2.1.4.2.5  Alternative Photodynamic Agent
	2.1.5  Therapeutic Angiogenesis
		2.1.5.1  Principles and Types of Therapeutic Angiogenesis
		2.1.5.2  Therapeutic Angiogenesis Products Under Development & Trial Results
			2.1.5.2.1  Genentech
			2.1.5.2.2  Chiron Corporation
			2.1.5.2.3  Vascular Genetics
			2.1.5.2.4  Collateral Therapeutics
			2.1.5.2.5  GenVec
		2.1.5.3 Hybrid Angiogenesis-PTMR Therapies
			2.1.5.3.1  Vascular Genetics/Biosense Webster
			2.1.5.3.2 Vical/Boston Scientific
			2.1.5.3.3 Cardiodyne
2.2  Management of Carotid Artery Occlusion and Stroke Prevention
	2.2.1  Carotid Endarterectomy
		2.2.1.1  Clinical Indications and Outcomes
			2.2.1.1.1  NASCET and ACAS Studies
			2.2.1.1.2  Study Limitations
		2.2.1.2  CEA Procedure Volumes
	2.2.2  Carotid Artery Stenting
		2.2.2.1  Targeted Indications
		2.2.2.2  Clinical Trial Results
			2.2.2.2.1  U.S. Data
				2.2.2.2.1.1  Findings Challenged
			2.2.2.2.2  CREST Trial Design
				2.2.2.2.2.1  Potential Market Impact
		2.2.2.3  Carotid Stenting Systems Under Development
			2.2.2.3.1  Bard Peripheral Technologies
			2.2.2.3.2 Boston Scientific
			2.2.2.3.3  Cordis
			2.2.2.3.4  Guidant
			2.2.2.3.5  Medtronic AVE
			2.2.2.3.6  Other Market Participants
	2.2.3  Embolic Containment Systems
		2.2.3.1  Targeted Indications
		2.2.3.2  Outcomes
		2.2.3.3  Embolic Containment Systems Under Development
			2.2.3.3.1 Cordis
			2.2.3.3.2  Boston Scientific
			2.2.3.3.3  Smaller Market Participants
				2.2.3.3.3.1  Embolic Protection, Inc.
				2.2.3.3.3.2  Kensey Nash
				2.2.3.3.3.3  Microvena Corporation
				2.2.3.3.3.4  Percusurge
			2.2.3.3.4  Other Market Participants
2.3  Abdominal Aortic Aneurysms
	2.3.1  Surgical Repair of Abdominal Aortic Aneurysms
	2.3.2  Aortic Aneurysm Repair With Endovascular Stent-Grafts
		2.3.2.1  Necessary Requirements for Successful SG Systems
		2.3.2.2  Limitations of Endovascular AAA Repair
			2.3.2.2.1  Endoleaks
				2.3.2.2.1.1  Preventing Endoleaks
				2.3.2.2.1.2  Outcomes from Endoleaks
			2.3.2.2.2  Endotension
		2.3.2.3  AAA Devices on the Market and Under Development
			2.3.2.3.1  Guidant
				2.3.2.3.1.1  Clinical Trial
			2.3.2.3.2  Medtronic AVE
				2.3.2.3.2.1  AneuRx Stent Graft System
				2.3.2.3.2.2  Talent SG
			2.3.2.3.3  W.L. Gore
			2.3.2.3.4  Boston Scientific
			2.3.2.3.5  Cook
			2.3.2.3.6  Cordis
			2.3.2.3.7  Edwards Lifesciences
			2.3.2.3.8  Sulzer Vascutek
2.4  Vascular Puncture Closure Systems
	2.4.1  Traditional Methods of Closure
		2.4.1.1  Limitations and Complications
	2.4.2  Vascular Puncture Closure Devices on the Market and Under Development
		2.4.2.1  Suture-Mediated Closure Systems
			2.4.2.1.1  Abbott Laboratories
				2.4.2.1.1.1  The Closer
			2.4.2.1.2  Sutura
			2.4.2.1.3  X-Site
			2.4.2.1.4  Scion
		2.4.2.2  Collagen Plug Devices
			2.4.2.2.1  St. Jude Medical/Kensey Nash
			2.4.2.2.2  Datascope
		2.4.2.3  Combination Products
			2.4.2.3.1  Vascular Solutions

Exhibit 2-1: Projected Procedure Mix in Interventional Management of Major Cardiovascular Disorders, 2000-2010 (#000)
Exhibit 2-2: U.S. Markets for Novel Cardiovascular Interventional Products, 1999-2010  ($mil)
Exhibit 2-3: Schema of Surgical TMR
Exhibit 2-4: "Outside-In"  Channels of TMR
Exhibit 2-5: Schema of PTMR
Exhibit 2-6:  "Inside-Out"  Channels
Exhibit 2-7: Eclipse's TMR 2000
Exhibit 2-8: Solo-Grip
Exhibit 2-9: Axcis Laser Catheter
Exhibit 2-10: DMR System
Exhibit 2-11: 3D Map
Exhibit 2-12: PeRFmr Catheter
Exhibit 2-13: Participants in the Emerging TMR/PTMR Market
Exhibit 2-14: Photoangioplasty/Vascular Photodynamic Therapy Systems Under Development
Exhibit 2-15: AutoFire System
Exhibit 2-16: AutoFire Catheter
Exhibit 2-17: Selected Therapeutic Angiogenesis Products Under Development
Exhibit 2-18: Application-Specific Carotid Stenting Systems in U.S. Clinical Trials
Exhibit 2-19: EMBOL-X•
Exhibit 2-20: FilterWire
Exhibit 2-21: Participants in the Emerging Percutaneous Embolic Containment System Market
Exhibit 2-22 Ancure System
Exhibit 2-23: Lifepath AAA Graft
Exhibit 2-24: Model of Anaconda
Exhibit 2-25: AAA Endovascular Repair Systems Currently on the Market and in Advanced Trials
Exhibit 2-26: Vasoseal ES
Exhibit 2-27: Duett Balloon Catheter
Exhibit 2-28: Vascular Puncture Closure Device on the U.S. Market and Under Development
 
Section 3:  Emerging U.S. Markets for Novel Cardiovascular Interventional Products

3.1  Coronary Revascularization Systems
	3.1.1  Transmyocardial Revascularization Product Markets
		3.1.1.1  Projected Growth
		3.1.1.2  Supplier Market Shares
	3.1.2  Photoangioplasty Therapy Market
		3.1.2.1  Projected Growth
	3.1.3  Therapeutic Angiogenesis Market
3.2  Emerging Stroke Prevention Product Markets
	3.2.1  Embolic Containment Systems
	3.2.2  Carotid Artery Stenting Systems
		3.2.2.1  Projected Growth
3.3  Endovascular Abdominal Aortic Aneurysm Repair Product Market
	3.3.1  Market Limitations
	3.3.2  Projected Growth
	3.3.3  Competitive Analysis
3.4  Vascular Puncture Closure Device Market
	3.4.1  Competitive Analysis

Exhibit 3-1: Novel Cardiovascular Therapeutic Modalities, Procedure Volume Forecast, 1999-2010
Exhibit 3-2: Novel Cardiovascular Therapy Systems, Market Forecast, 1999-2010 ($ mil)
Exhibit 3-3: TMR/PTMR Patient Caseloads and Procedure Volumes, 1999-2010 (#000)
Exhibit 3-4: U.S. Markets for TMR & PTMR Disposable Kit Products, 1999-2010
Exhibit 3-5: Estimated Market Shares of the U.S. Suppliers of TMR Products, 1999
Exhibit 3-6: Projected Dynamics of Coronary Photoangioplasty Procedures
Exhibit 3-7: Emerging U.S. Market for Photoangioplasty Agents
Exhibit 3-8: Projected Dynamics of Coronary Angiogenesis Procedures
Exhibit 3-9: Emerging U.S. Market for Therapeutic Angiogenesis Agents
Exhibit 3-10: Projected Utilization Pattern of Embolic Containment Systems
Exhibit 3-11: Emerging U.S. Market for Embolic Containment Systems
Exhibit 3-12: Carotid Artery Stenosis Patient Caseloads and Procedure Volumes, 1999-2010 (#000)
Exhibit 3-13: Emerging U.S. Market for Carotid Artery Stents, 1999-2010
Exhibit 3-14: AAA Patient Caseloads and Procedure Volumes, 1999-2010 (#000)
Exhibit 3-15: U.S. Markets for AAA Repair Endografts, 1999-2010
Exhibit 3-16: Estimated 2000 Market Shares of the U.S. Suppliers of AAA Endografts
Exhibit 3-17: Projected Dynamics of Vascular Puncture Closure Procedures, 1999-2010
Exhibit 3-18 U.S. Market for Vascular Puncture Closure Devices, 1999-2010
Exhibit 3-19: Market Shares of the U.S. Suppliers of Vascular Puncture Closure Devices, 1999
 
Section 4:  Company Profiles

4.1  Abbott Laboratories/Perclose
	4.1.1  Perclose
4.2  C.R. Bard
4.3  Boston Scientific Corporation
4.4  Collateral Therapeutics
4.5  Datascope Corporation
4.6  Eclipse Surgical Technologies
4.7  Edwards Lifesciences
4.8  Genentech (Angiogenesis)
4.9  Guidant Corporation
4.10  Johnson & Johnson/Biosense Webster, Cordis
4.11  Medtronic
4.12  PercuSurge, Inc.
4.13  Pharmacyclics
4.14  PLC Systems, Inc.
4.15  St Jude Medical, Inc.



COMPANIES COVERED:

  1. Abbott Laboratories / Perclose
  2. Perclose
  3. C.R. Bard
  4. Boston Scientific Corporation
  5. Collateral Therapeutics
  6. Datascope Corporation
  7. Eclipse Surgical Technologies
  8. Edwards Lifesciences
  9. Genentech (Angiogenesis)
  10. Guidant Corporation
  11. Johnson & Johnson / Biosense Webster, Cordis Medtronic
  12. PercuSurge, Inc.
  13. Pharmacyclics
  14. PLC Systems, Inc.
  15. St Jude Medical, Inc
Contact Us

Need help finding medtech research? Let us help you!